Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
BOC 2026 | Prof. Xinan Sheng: RC48-C016 Redefines First-Line Treatment for Advanced Urothelial Carcinoma, While Sequential ADC Strategies Open New Horizons in Later-Line Therapy
2026.07.25
Pujiang Prostate Cancer Conference | Prof. Xiaojie Bian: Translating the Latest ASCO Advances into Precision Prostate Cancer Care and Driving Innovation in China
2026.07.25
Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation
2026.07.25
Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice
2026.07.25
Pujiang Prostate Cancer Conference | Prof. Bo Dai Shares Clinical Experience with the Hood Technique for Robot-Assisted Radical Prostatectomy
2026.07.25
BOC Spotlight on Precision HER2 Therapy | Disitamab Vedotin Sets a New Benchmark for China’s Homegrown Innovation
2026.07.24
Pujiang Prostate Cancer Conference | Prof. Xiaojian Qin Discusses the Clinical Value and Surgical Experience of Primary Tumor Resection in Metastatic Prostate Cancer
2026.07.24
Pujiang Prostate Cancer Conference | Prof. Yong Yang: The Predictive Value of Deep PSA Response and Treatment Optimization in mHSPC
2026.07.24
ASCO China Voice | Professors Claudio Vernieri & Man Li: PALMARES-2 Highlights the Potential of CDK4/6 Inhibitor Beyond Progression and Combined Local Therapy
2026.07.24
Rethinking the Limits of Flexible Ureteroscopy — An Interview with Prof. John D. Denstedt
2026.07.24
Posted inUroStream

BOC 2026 | Prof. Xinan Sheng: RC48-C016 Redefines First-Line Treatment for Advanced Urothelial Carcinoma, While Sequential ADC Strategies Open New Horizons in Later-Line Therapy

Posted by By Peng Geng 2026.07.25
Continue Reading
Posted inIOncology

Pujiang Prostate Cancer Conference | Prof. Xiaojie Bian: Translating the Latest ASCO Advances into Precision Prostate Cancer Care and Driving Innovation in China

Posted by By Peng Longmei 2026.07.25
Continue Reading
Can minor histocompatibility antigens (mHAgs) unlock new predictive power in GvHD risk stratification?

Can minor histocompatibility antigens (mHAgs) unlock new predictive power in GvHD risk stratification?

Posted by By Peng Longmei 2025.04.12
At EBMT 2025, Dr. Nicoletta Cieri (Dana-Farber Cancer Institute) delivered a forward-looking presentation exploring the prognostic potential of mHAg load in allogeneic hematopoietic cell transplantation (allo-HCT).Her findings suggest that systematic…
Read More
EBMT 2025 | GVHD Prophylaxis in Haploidentical HSCT for R/R AML: Insights from Dr. Giorgia Battipaglia

EBMT 2025 | GVHD Prophylaxis in Haploidentical HSCT for R/R AML: Insights from Dr. Giorgia Battipaglia

Posted by By Mourabit Halima 2025.04.12
At EBMT 2025, Dr. Giorgia Battipaglia shared important findings from a multicenter study comparing post-transplant cyclophosphamide (PTCy) versus antithymocyte globulin (ATG) as GVHD prophylaxis in patients with relapsed/refractory AML undergoing…
Read More
GVHD Prophylaxis in Intermediate-Risk AML: Mixed Results from a Multicenter Trial

GVHD Prophylaxis in Intermediate-Risk AML: Mixed Results from a Multicenter Trial

Posted by By Mourabit Halima 2025.04.12
At EBMT 2025, Dr. Edouard Forcade presented the results of a multicenter randomized trial comparing cyclosporine (CsA) alone versus CsA plus mycophenolate mofetil (MMF) in patients with intermediate-risk AML in…
Read More
ASCO GI 2025 | Prof. Ying Yuan & Prof. Kefeng Ding on BB+CAPOX in RAS-Mutant MSS mCRC

ASCO GI 2025 | Prof. Ying Yuan & Prof. Kefeng Ding on BB+CAPOX in RAS-Mutant MSS mCRC

Posted by By Yin, Jiale 2025.04.12
At ASCO GI 2025, Prof. Ying Yuan shared updated data from the BB+CAPOX Phase II trial, showing a median PFS of 25.3 months in liver-only RAS-mutant MSS mCRC. Prof. Kefeng Ding highlighted the potential of this combo to convert immune-cold tumors into responsive disease.
Read More
ASCO GI 2025 | Spotlight on SHR1701 from Peking University Cancer Hospital

ASCO GI 2025 | Spotlight on SHR1701 from Peking University Cancer Hospital

Posted by By Mourabit Halima 2025.04.11
At the ASCO GI 2025 Symposium in San Francisco, experts from Peking University Cancer Hospital presented new data on SHR1701, a PD-L1/TGF-βR2 fusion protein. The Phase III results showed both survival benefits and a reduction in chemotherapy-induced myelosuppression in advanced gastric and GEJ cancers.
Read More
Sebastian Giebel Presents at EBMT 2025: How Prior alloHCT Shapes CART19 Outcomes in B-ALL

Sebastian Giebel Presents at EBMT 2025: How Prior alloHCT Shapes CART19 Outcomes in B-ALL

Posted by By Mourabit Halima 2025.04.11
At EBMT 2025, Professor Sebastian Giebel shared key data from a real-world, multicenter study on CART19 therapy in 345 B-ALL patients. The study highlights how prior alloHCT exposure impacts survival…
Read More
EBMT 2025 | Dr. maria victoria mateos manteca on MRD as a Surrogate Marker in Myeloma Outcomes

EBMT 2025 | Dr. maria victoria mateos manteca on MRD as a Surrogate Marker in Myeloma Outcomes

Posted by By Peter W. PENG 2025.04.11
At this year’s EBMT Annual Meeting, Dr. María-Victoria Mateos (Salamanca, Spain) delivered an impactful presentation titled “MRD in Myeloma as Surrogate Marker for Outcomes.”
Read More
Allogeneic SCT in Follicular Lymphoma: Still a Valid Option in the Modern Therapeutic Landscape

Allogeneic SCT in Follicular Lymphoma: Still a Valid Option in the Modern Therapeutic Landscape

Posted by By Mourabit Halima 2025.04.11
At EBMT 2025, Yasmina Serroukh from Erasmus MC presented a benchmark study evaluating the role of allogeneic stem cell transplantation (allo-SCT) in follicular lymphoma (FL). The analysis, drawn from a…
Read More
Prof. Heiner Wedemeyer on the Unfinished Mission of HCV Elimination

Prof. Heiner Wedemeyer on the Unfinished Mission of HCV Elimination

Posted by By Peng Longmei 2025.04.11
In a recent editorial published in the Journal of Hepatology (April 2025), Prof. Heiner Wedemeyer (Hannover Medical School) a leading voice in hepatology joined Niklas Luhmann in reflecting on more…
Read More
Can we truly personalize leukemia-free survival prediction after allo-HCT?

Can we truly personalize leukemia-free survival prediction after allo-HCT?

Posted by By Mourabit Halima 2025.04.11
At EBMT 2025, Professor Alexandros Spyridonidis delivered a compelling presentation addressing one of the most pressing challenges in hematopoietic stem cell transplantation: how to provide patients with accurate, individualized prognostic information.
Read More

Posts pagination

Previous page 1 … 20
Recent Posts
  • BOC 2026 | Prof. Xinan Sheng: RC48-C016 Redefines First-Line Treatment for Advanced Urothelial Carcinoma, While Sequential ADC Strategies Open New Horizons in Later-Line Therapy
  • Pujiang Prostate Cancer Conference | Prof. Xiaojie Bian: Translating the Latest ASCO Advances into Precision Prostate Cancer Care and Driving Innovation in China
  • Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation
  • Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice
  • Pujiang Prostate Cancer Conference | Prof. Bo Dai Shares Clinical Experience with the Hood Technique for Robot-Assisted Radical Prostatectomy
Recent Comments
    Archives
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inUroStream
    BOC 2026 | Prof. Xinan Sheng: RC48-C016 Redefines First-Line Treatment for Advanced Urothelial Carcinoma, While Sequential ADC Strategies Open New Horizons in Later-Line Therapy
    Posted by By Peng Geng 2026.07.25
    Posted inIOncology
    Pujiang Prostate Cancer Conference | Prof. Xiaojie Bian: Translating the Latest ASCO Advances into Precision Prostate Cancer Care and Driving Innovation in China
    Posted by By Peng Longmei 2026.07.25
    Posted inIOncology
    Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation
    Posted by By Mourabit Halima 2026.07.25
    Posted inIOncology
    Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice
    Posted by By Mourabit Halima 2026.07.25
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied